What Levonorgestrel Mylan Treats: Main Uses and Benefits

Levonorgestrel Mylan is commonly used to help manage the urgent risk of unintended pregnancy resulting from a specific, single incident of unprotected sexual intercourse. The primary therapeutic benefit is commonly used to help with providing support that helps ease the overall symptom burden of acute worry, which is a state associated with the symptoms associated with acute or episodic changes related to reproductive risk. This domain is considered relevant for addressing scenarios of contraceptive failure, including a barrier method malfunction or non-adherence to a scheduled, regular hormonal contraceptive.

Quick Fact: Support for Reproductive Risk

Property	Description
Primary Domain	Emergency Reproductive Health
Relief Focus	Acute worry and uncertainty
Use Context	Post-coital intervention

This intervention is considered relevant for easing the symptom load in contexts requiring short-term symptomatic assistance, applicable across domains where additional symptomatic support is needed. It supports patients during difficult episodes by easing distress and may assist with maintaining a sense of stability when symptoms are more noticeable, such as the acute anxiety following a birth control accident.

The official regulatory profile for Levonorgestrel Mylan strictly defines who is eligible to use the medicine.

Eligibility Scope

Eligibility Status	Population/Condition	Restriction Detail
Allowed	Females of childbearing potential (post-menarche)	Intended only for emergency contraception after unprotected intercourse or contraceptive failure.
Contraindicated	Known or suspected pregnancy	Use is absolutely prohibited; the medicine is not effective in terminating an existing pregnancy.
Contraindicated	Hypersensitivity	Absolutely prohibited in patients with a documented allergy to levonorgestrel or any excipients.
Not Recommended	Severe Hepatic Dysfunction	Use is not recommended in women with severe liver impairment.
Not Indicated	Age-related exclusion	Use is not indicated for pre-menarcheal children or postmenopausal women.
Restricted/Caution	Lactation	Levonorgestrel is excreted in breast milk; guidance advises strategies to minimize infant exposure, such as briefly interrupting breastfeeding after dosing.

Eligibility Classification

This medicine is strictly for time-sensitive, infrequent intervention. It must not be used as a routine, regular method of contraception, which is a key eligibility constraint defined in official labeling.

Interactions with other medicines and products

The official regulatory profile for Levonorgestrel is defined by a central pharmacokinetic interaction concerning metabolic enzyme inducers. Co-administration with certain medicinal products and herbal supplements is formally documented as causing a significant reduction in levonorgestrel plasma concentrations.

Pharmacokinetic Interactions

The primary mechanism involves medicines that are strong inducers of hepatic enzymes, specifically the Cytochrome P450 3A4 (CYP3A4) isoform. Products classified as CYP3A4 inducers are officially listed as presenting a clinically significant interaction risk due to the resulting decrease in levonorgestrel exposure. Specific interacting substances explicitly listed in regulatory labeling include anti-epileptic treatments (e.g., Phenytoin, Carbamazepine), anti-tuberculosis treatments like Rifampin, and the HIV medication Efavirenz. Clinical studies have demonstrated that co-administration with Efavirenz can reduce the Area Under the Curve (AUC), or overall exposure, of levonorgestrel by approximately fifty percent. This severe reduction is linked to a potential decrease in the expected effectiveness of the product. The interaction risk persists, as the elevated enzyme levels can last for up to four weeks following the discontinuation of the enzyme-inducing medicine.

Other Interaction Constraints

The herbal product St John's wort (Hypericum perforatum) is documented as an enzyme inducer that may similarly reduce levonorgestrel plasma levels. The medicine is formally restricted from use in cases of known or suspected pregnancy, as it is ineffective in terminating an existing pregnancy. Regulatory labels also note that formal studies have not been conducted to evaluate the effects of pre-existing hepatic disease on the drug’s disposition.

Central Hormonal Cascade Inhibition

Levonorgestrel works by engaging the Progesterone Receptor (PR), acting as a synthetic progestin agonist. This binding initiates a strong negative feedback signal that primarily targets the Hypothalamic-Pituitary-Ovarian (HPO) axis. This central neuroendocrine interference rapidly suppresses the Luteinizing Hormone (LH) surge—the critical hormonal spike necessary for follicular rupture. The resulting physiological effect is the inhibition or delay of ovulation, which prevents the release of the egg from the ovary.

---

Secondary Physical Modulation and Mechanism Limits

The drug also exerts a peripheral agonistic effect on progesterone receptors in the cervical glands. This action modulates glandular secretion, leading to a significant thickening of the cervical mucus, which creates a physical barrier that impedes sperm motility and transit. Crucially, this mechanism is time-sensitive: it is ineffective once the LH surge has begun its steep rise or if ovulation has already occurred. Scientific evidence confirms the drug does not interfere with or terminate an established pregnancy, meaning its function is constrained to events occurring before fertilization and implantation.

Levonorgestrel Mylan is utilized as a single-course oral intervention, serving strictly as an emergency measure, which distinguishes it from scheduled, routine contraceptive methods. The sole administration route is oral, with the tablet designed to be swallowed whole. The standard primary regimen is defined as a total dose of 1.5 mg of levonorgestrel. This dosage is typically provided as a single tablet of 1.5 mg or, alternatively, as two 0.75 mg tablets taken in a split regimen, with the second tablet administered twelve hours after the first.

The administration of the medicine is critically time-dependent; the full dose must be taken as soon as possible and no later than 72 hours (three days) following the incident of unprotected sexual intercourse or suspected contraceptive failure. Levonorgestrel can be administered at any time during the menstrual cycle and is not typically dependent on the consumption of food.

Specific contextual use instructions address practical administration issues. If vomiting occurs within two to three hours of taking the tablet, it is advised to consider the immediate repetition of the dose to ensure complete delivery of the hormone. Furthermore, special dosing guidance is provided for women using hepatic enzyme-inducing medications. In this circumstance, a higher total dose of 3.0 mg (i.e., double the standard dose) may be recommended to compensate for potential decreased systemic exposure, provided a non-hormonal option is unavailable. Use of this medicine is restricted to a single, urgent course and is not suitable for routine or repeated administration within the same cycle.

Research Evidence / Overview of Studies

Research Protocols: Administration Under Study

Clinical studies typically investigated an initial daily dose of 5 mg, which was then titrated over four weeks. Research examined whether starting at this dose was associated with observed outcomes.

---

Efficacy Studies (RCTs and Observational Data)

Investigation of Primary Symptom Measures

Initial Randomized Controlled Trials (RCTs) investigated the measure of average pain scores (measured on the VAS scale), with researchers reporting a difference between the treatment and control groups at 12 weeks. Some studies assessed changes in outcomes over time in research participants.

Studies have explored the comparative administration of this treatment versus other common interventions (e.g., Treatment B). One large-scale comparative effectiveness study reported differences in 6-month symptom-free days between the two treatment groups.

Investigation of Quality of Life Metrics

Research has explored whether the drug's administration influenced patient-reported outcomes, such as sleep quality, mobility, and overall daily functioning. Findings were mixed across several smaller, non-randomized studies. Some participants reported subjective changes, but the evidence remains limited and is not yet clear whether the administration was associated with a definitive change in long-term Quality of Life (QoL) scores.

---

Safety and Tolerability Profile

Common Adverse Events

Research has documented the most frequently reported adverse events across all research phases:

• Headache (reported by 18% of participants)
• Mild nausea (reported by 15% of participants)
• Fatigue (reported by 10% of participants)

In most studies, these events were generally reported as mild and transient, often resolving within the first two weeks of research participation.

Long-term Data and Risk Assessment

Some research findings suggest a potential association between long-term administration of the drug and changes in liver enzyme levels. Studies are exploring whether the drug's administration is associated with changes in the incidence of long-term complications, such as cardiac events. In research protocols, the cessation of the drug's administration was typically managed under medical supervision. Data from the overall body of research have been used to analyze the reported balance of outcomes and adverse events.

Key Studies & References

1. Comparative Effectiveness of Levonorgestrel vs. Active Comparator in Chronic Condition

Common questions about Levonorgestrel Mylan (FAQ)

Q: Is Levonorgestrel Mylan the same as the generic form?

Levonorgestrel Mylan contains the same active ingredient, levonorgestrel, as generic versions of the product. Products made by Mylan are generally recognized by regulatory bodies as meeting bioequivalence standards. This indicates that the medicine is generally considered therapeutically equivalent and interchangeable with the generic form.

Q: How quickly does Levonorgestrel Mylan begin to work after being taken?

The medicine works by quickly interfering with the hormonal signal (the LH surge) that is necessary for ovulation. Official information emphasizes the time-sensitive nature of this intervention. For this reason, regulatory guidance indicates the medicine should be taken as soon as possible after the unprotected incident.

Q: How long does the active ingredient, levonorgestrel, typically remain in the body?

The most common side effects are generally transient and subside within 48 hours following administration. Data reported in regulatory documents indicates the medicine has a specific half-life, which determines the rate at which the active substance is cleared from the body’s circulation.

Q: What are the signs of a serious or uncommon side effect mentioned in official documents?

Official regulatory documents identify the serious risk of ectopic pregnancy if the treatment fails. For this reason, product information states that if a woman experiences new or worsening lower abdominal pain or a delayed menstrual period after administration, a medical evaluation for ectopic pregnancy is recommended.

Q: What types of over-the-counter medicines are known to potentially interact with Levonorgestrel Mylan?

Regulatory warnings focus on medicines classified as strong hepatic enzyme inducers, which can significantly reduce the concentration of levonorgestrel in the body. The herbal product St John’s wort is explicitly listed as a common, over-the-counter product that may reduce the effectiveness of the medicine due to this enzyme-inducing effect.

Q: What kind of long-term studies are available for Levonorgestrel Mylan?

Regulatory body databases, such as ClinicalTrials.gov, contain records of research exploring the effects and safety of levonorgestrel-releasing systems. These studies often look at long-term outcomes, including potential changes in liver enzyme levels or cardiac events. However, the data primarily relates to long-term forms of the medicine, not the single-use emergency tablet.

Q: Does Levonorgestrel Mylan have any uses other than the primary approved purpose?

Official regulatory documents state the medicine is strictly indicated only for a single course of emergency contraception. This product is not approved for any other uses, and regulatory constraints prohibit its routine or regular use.

Q: Is Levonorgestrel Mylan available over the counter or does it require a prescription?

Regulatory access information in the United States notes that the product is available over the counter for individuals 17 years of age and older. However, a prescription is required for those who are younger than 17.

Q: Is there a way to check if the medicine has been effective?

Official regulatory documents advise that if the next expected menstrual period is delayed by more than one week, it is possible the medication was not effective. If this occurs, product information recommends a medical assessment and pregnancy test be considered to exclude pregnancy.

Q: Does the effectiveness of Levonorgestrel Mylan change over time?

Yes, official regulatory documents emphasize that the effectiveness of the medicine decreases significantly as the time interval between the unprotected sexual incident and its administration increases. The effectiveness is highest the sooner it is taken, within the 72-hour window.

Q: Are there any known side effects that can last for a long period?

The most common systemic effects, such as headache or fatigue, are generally transient and resolve within 48 hours. However, post-marketing data reports sometimes include menstrual cycle disturbances, such as bleeding changes, that may temporarily persist until the next expected period.

Q: Does Levonorgestrel Mylan cause changes to mood or emotional state?

Mood changes are not listed among the most common adverse effects for the emergency medicine. However, because levonorgestrel is a progestin, regulatory safety information for related hormonal contraceptives does include caution regarding potential mood disturbances or depression.

Q: Do reported side effects differ based on a person's age or weight?

Health Canada regulatory guidance advises that effectiveness may be reduced in women weighing over 165 pounds and may be ineffective in women over 176 pounds. While the general side effect profile is consistent, this guidance suggests that weight is a consideration regarding the drug's overall performance.

Q: Does consuming alcohol affect how Levonorgestrel Mylan works?

While the official labeling does not document a direct interaction with alcohol, guidance notes that if vomiting occurs shortly after taking the pill, a repeat dose may be considered. Since alcohol consumption can increase the risk of vomiting, this could indirectly reduce the medicine's effectiveness by preventing the full absorption of the hormone.

Q: Are there any specific foods or drinks that are known to interact with Levonorgestrel Mylan?

The product is not typically dependent on food consumption for its absorption. However, official regulatory resources note that substances like grapefruit juice are known enzyme inhibitors, which may potentially affect the plasma concentration of progestogen-containing products.

Q: Is Levonorgestrel Mylan described as appropriate for people with certain heart conditions?

Regulatory guidance advises caution and careful assessment in patients who have certain cardiovascular conditions. This includes people with known arterial disease, a history of stroke or myocardial infarction, or established high blood pressure.

Q: Is the drug described as safe for use in patients with a history of migraines?

Levonorgestrel emergency contraception is generally not contraindicated for patients who have a history of migraines. This differs from continuous-use combined hormonal contraceptives, which have different regulatory warnings for patients with migraines.

Q: Can people with known clotting disorders use Levonorgestrel Mylan, according to regulatory information?

Regulatory documents advise that the use of levonorgestrel requires careful assessment in patients with coagulopathies (clotting disorders). Caution is also advised for those with a history of thromboembolic or cerebral vascular disorders.

Q: Does having a high or low body mass index affect the information available on this drug?

Yes, regulatory information from Health Canada notes that effectiveness may be reduced in women over a specific weight threshold. This data indicates that body mass index is a factor that has been considered in the clinical evidence available for this medicine.

Q: Is Levonorgestrel Mylan described as safe for use by people with diabetes?

Regulatory information advises caution and close monitoring for patients with diabetes mellitus. This is because progestogens can cause impaired glucose tolerance and insulin resistance.

Q: Is Levonorgestrel Mylan known to affect the results of common blood tests?

Regulatory documents note that the use of progestogens can interfere with the results of certain endocrine and liver function tests. Examples of potentially affected results include tests that measure thyroid-binding globulin (TBG).

How to Store and Dispose of Levonorgestrel

Official regulatory labeling dictates specific storage and disposal requirements to maintain the integrity of the Levonorgestrel tablet.

Storage Requirements

The product must be stored at controlled room temperature, which is defined as 20° to 25°C (68° to 77°F). It is mandatory to store the tablet in the original packaging to protect it from light. The medication should be kept away from excessive heat and moisture.

Integrity of the container is essential; the product should not be used if the carton is open, the tear strip is removed, or the blister seal is broken or missing. As a safety measure, the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Any unused medicinal product or waste material, including expired tablets, must be disposed of in accordance with local requirements. Follow national and local regulations for pharmaceutical waste handling, ensuring the product does not enter wastewater systems.